Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Insider Purchases $987,000.00 in Stock

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) insider Carl Hull acquired 175,000 shares of Maravai LifeSciences stock in a transaction dated Monday, November 11th. The shares were bought at an average cost of $5.64 per share, with a total value of $987,000.00. Following the completion of the purchase, the insider now owns 175,000 shares in the company, valued at approximately $987,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Maravai LifeSciences Stock Performance

Shares of NASDAQ MRVI opened at $5.20 on Friday. The business’s 50 day moving average is $7.92 and its two-hundred day moving average is $8.46. The company has a market cap of $1.31 billion, a P/E ratio of -3.18 and a beta of 0.02. The company has a quick ratio of 9.28, a current ratio of 10.00 and a debt-to-equity ratio of 0.71. Maravai LifeSciences Holdings, Inc. has a 12 month low of $4.68 and a 12 month high of $11.56.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC grew its position in Maravai LifeSciences by 310.2% during the second quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock worth $26,000 after buying an additional 2,711 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Maravai LifeSciences in the 2nd quarter worth approximately $32,000. Headlands Technologies LLC acquired a new stake in shares of Maravai LifeSciences during the 1st quarter worth approximately $42,000. Blue Trust Inc. bought a new stake in shares of Maravai LifeSciences during the second quarter valued at approximately $44,000. Finally, Venturi Wealth Management LLC acquired a new position in shares of Maravai LifeSciences in the third quarter valued at $47,000. Institutional investors own 50.25% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. UBS Group boosted their target price on shares of Maravai LifeSciences from $8.50 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, August 8th. Robert W. Baird reduced their price target on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Morgan Stanley lowered shares of Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $11.00 to $10.00 in a research note on Tuesday, August 13th. Royal Bank of Canada decreased their target price on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Finally, The Goldman Sachs Group dropped their price target on shares of Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 8th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Maravai LifeSciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.33.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.